Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Open accessThe DOI matches its Crossref record; 339 of the 341 references it cites were found in a registry or an index.
Abstract
Background: Pharmacological augmentation is a recommended strategy for patients with treatment-resistant depression. A range of guidelines provide advice on treatment selection, prescription, monitoring and discontinuation, but variation in the content and quality of guidelines may limit the provision of objective, evidence-based care. This is of importance given the side effect burden and poorer long-term outcomes associated with polypharmacy and treatment-resistant depression. This review provides a definitive overview of pharmacological augmentation recommendations by assessing the quality of guidelines for depression and comparing the recommendations made. Methods: A systematic literature search identified current treatment guidelines for depression published in English. Guidelines were quality assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Data relating to the prescription of pharmacological augmenters were extracted from those developed with sufficient rigor, and the included recommendations compared. Results: Total of 1696 records were identified, 19 guidelines were assessed for quality, and 10 were included. Guidelines differed in their quality, the stage at which augmentation was recommended, the agents included, and the evidence base cited. Lithium and atypical antipsychotics were recommended by all 10, though the specific advice was not consistent. Of the 15 augmenters identified, no others were universally recommended. Conclusions: This review provides a comprehensive overview of current pharmacological augmentation recommendations for major depression and will support clinicians in selecting appropriate treatment guidance. Although some variation can be accounted for by date of guideline publication, and limited evidence from clinical trials, there is a clear need for greater consistency across guidelines to ensure patients receive consistent evidence-based care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Clinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 3×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundThe Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,510
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Goodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Self-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Self-citationLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920
Lithium toxicity profile: a systematic review and meta-analysis
McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61516-x · Cited by 877
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · cited 29×
“General side effect and/or monitoring/drug interaction guidance for AAPs was provided by APA, TMAP, the MPG, RANZCP, BAP, and CANMAT (Tables 5 and 6).”
BackgroundInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797 · cited 1×
“However, for the 25% to 50% of patients reported to have a poor response to at least 2 different antidepressant treatments (Fava and Davidson, 1996; Rush et al., 2006), outcomes can be improved with successive and multimodal treatment (Rush et al.”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 1×
“RANZCP and the BAP both considered a study by Murrough and colleagues (2013) as evidence for its success as a short-term treatment (Murrough et al., 2013) and highlighted potential adverse events and toxicity (Price et al.”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Self-citation(1997) · PubMed · Cited by 727
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 1×
“ketamine as a second-line augmenter and highlighted the potential for this to be superseded by its intranasal form in the near future (Daly et al., 2018).”
BackgroundSafety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Sackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686 · cited 3×
“, 2006), but lithium plus an antidepressant more effective than antidepressant monotherapy in preventing relapse in TRD patients who responded to lithium augmentation or ECT (Bauer et al., 2000; Sackeim et al., 2001).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Osborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.242 · Cited by 608 · cited 1×
“, 2013), MPG Coronary heart disease/risk of sudden cardiac death MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013) Extrapyramidal side effects (including tardive dyskinesia and neuroleptic…”
BackgroundQTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558 · cited 1×
“The MPG acknowledged that the adverse effects associated with ketamine may be underestimated in the literature (Short et al., 2018), and advised a pretreatment ECG (Aan het Rot et al.”
BackgroundNelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · cited 6×
“They also referred to 2 meta-analyses in which response and remission rates were significantly better for AAP augmentation than placebo (Papakostas et al., 2007; Nelson and Papakostas, 2009).”
BackgroundMethodResultInfluentialSignificance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini, R. J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250095013 · Cited by 545
Lithium toxicity profi le: a systematic review and meta-analysis
McKnight, R. F., Budge, K., Ba, S., Goodwin, G. M., Geddes, J. R., & Adida, M. (2012) · Cited by 544
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518 · cited 2×
“NICE concluded that the evidence for clinical efficacy was “moderate” and cautioned that dropout and side-effect reports were more likely than for antidepressant monotherapy, particularly for quetiapine (Shelton et al., 2001; Corya et al., 2006; Berman et al., 2007; Mahmoud et al., 2007; McIntyre et al., 2007; Song et…”
BackgroundA Novel Augmentation Strategy for Treating Resistant Major Depression
Shelton, R. C., Tollefson, G. D., Tohen, M., Stahl, S., Gannon, K. S., Jacobs, T. G., Buras, W. R., Bymaster, F. P., Zhang, W., Spencer, K. A., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.131 · Cited by 504 · cited 1×
“trials report rapid improvements in mood, but the difference is modest compared with placebo (Shelton et al., 2001; Corya et al., 2006; Berman et al., 2007; Dorée et al., 2007; Mahmoud et al., 2007; McIntyre et al., 2007; Thase et al., 2007a; Garakani et al., 2008; Keitner et al., 2009).”
ResultLeucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Triiodothyronine Augmentation in the Treatment of Refractory Depression: A Meta-analysis
Aronson, R. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090090013 · Cited by 488 · cited 30×
“General side effect and/or monitoring/drug interaction guidance for AAPs was provided by APA, TMAP, the MPG, RANZCP, BAP, and CANMAT (Tables 5 and 6).”
BackgroundInfluentialA Reevaluation of Risk of In Utero Exposure to Lithium
Cohen, L. S. (1994) · JAMA · doi:10.1001/jama.1994.03510260078033 · Cited by 475
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
The importance of drug interactions in epilepsy therapy
Patsalos, P. N., Fröscher, W., Pisani, F., & Van Rijn, C. M. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.13001.x · Cited by 455
Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death
Haddad, P. M., & Anderson, I. M. (2002) · Drugs · doi:10.2165/00003495-200262110-00006 · Cited by 435 · cited 3×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Antipsychotics and the Risk of Sudden Cardiac Death
Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K., & Murray, K. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.12.1161 · Cited by 429
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 21×
“Supported their recommendations with conflicting evidence demonstrating that lithium had nonsignificant benefit over placebo or antidepressants for prophylaxis (Burgess et al., 2001; Cipriani et al., 2006), but lithium plus an antidepressant more effective than antidepressant monotherapy in preventing relapse in TRD p…”
ResultInfluentialKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418
Berman, R. M., Marcus, R. N., Swanink, R., McQuade, R. D., Carson, W. H., Corey-Lisle, P. K., & Khan, A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0604 · Cited by 409
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
Spina, E., Santoro, V., & D'Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 361
Drug Prescribing in Renal Failure: Dosing Guidelines for Adults.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-502_4 · Cited by 360
Treatment of patients with eating disorders,third edition. American Psychiatric Association.
(2006) · PubMed · Cited by 354
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub4 · Cited by 348
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Ketamine administration in depressive disorders: a systematic review and meta-analysis
Fond, G., Loundou, A., Rabu, C., Macgregor, A., Lançon, C., Brittner, M., Micoulaud-Franchi, J.-A., Richieri, R., Courtet, P., Abbar, M., et al. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3664-5 · Cited by 339
Zhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
Papakostas, G. I., Nutt, D. J., Hallett, L. A., Tucker, V. L., Krishen, A., & Fava, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.015 · Cited by 334
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · cited 2×
“NICE did not recommend lamotrigine, carbamazepine, or valproate as they considered the evidence inadequate at the time of publication (Hurley, 2002; Normann et al., 2002; Barbosa et al., 2003; Schindler and Anghelescu, 2007b; Santos et al., 2008) as did CANMAT (Zhou et al., 2015).”
BackgroundQT interval and antidepressant use: a cross sectional study of electronic health records
Castro, V. M., Clements, C. C., Murphy, S. N., Gainer, V. S., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Iosifescu, D. V., et al. (2013) · BMJ · doi:10.1136/bmj.f288 · Cited by 315
Shine, B., McKnight, R. F., Leaver, L., & Geddes, J. R. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61842-0 · Cited by 313
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.611 · Cited by 306
Lithium Augmentation in Treatment-Resistant Depression: Meta-Analysis of Placebo-Controlled Studies
Bauer, M., & Döpfmer, S. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00006 · Cited by 304
Fekadu, A., Wooderson, S. C., Markopoulo, K., Donaldson, C., Papadopoulos, A., & Cleare, A. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.014 · Cited by 299
Self-citationThe Maudsley Prescribing Guidelines in Psychiatry (Full-Text Access)
(2025) · The Maudsley Prescribing Guidelines in Psychiatry · doi:10.1002/9781119870203.mpg016 · Cited by 290
The use of ketamine as an antidepressant: a systematic review and meta‐analysis
Coyle, C. M., & Laws, K. R. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2475 · Cited by 279 · cited 1×
“CANMAT recommend ketamine as an experimental adjunctive agent in an academic setting but echoed caution against adverse reactions, potential abuse, and its efficacy long term (Fond et al., 2014b; Serafini et al., 2014a; Coyle and Laws, 2015; Wan et al., 2015).”
BackgroundSpielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275 · cited 2×
“CANMAT referred to 4 additional meta-analyses (again including Nelson and Papakostas, 2009), each including 12–17 trials and reporting better efficacy for aripiprazole, quetiapine, olanzapine, and risperidone compared with placebo, with small to medium effect sizes (Komossa et al., 2010; Spielmans et al., 2013; Wen et…”
MethodResultTreatment of patients with substance use disorders, second edition. American Psychiatic Association.
Kleber, H. D., Weiss, R. D., Anton, R. F., George, T. P., Greenfield, S. F., Kosten, T. R., O’Brien, C. P., Rounsaville, B. J., Strain, E. C., Ziedonis, D. M., et al. (2006) · PubMed · Cited by 265
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0270 · Cited by 262
Hennessy, S., Bilker, W. B., Knauss, J. S., Margolis, D. J., Kimmel, S. E., Reynolds, R. F., Glasser, D. B., Morrison, M. F., & Strom, B. L. (2002) · BMJ · doi:10.1136/bmj.325.7372.1070 · Cited by 261 · cited 1×
“, 2013), MPG Coronary heart disease/risk of sudden cardiac death MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013) Extrapyramidal side effects (including tardive dyskinesia and neuroleptic…”
BackgroundAntipsychotics and the Risk of Sudden Cardiac Death
Straus, S. M. J. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., ‘t Jong, G. W., Kingma, J. H., Sturkenboom, M. C. J. M., & Stricker, B. H. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.12.1293 · Cited by 260
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Joffe, R. T. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820170065008 · Cited by 258 · cited 12×
“The BAP recommended lithium as a first-line augmenter but cautioned that most studies augmented TCAs and the association with side effects.”
BackgroundInfluential15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258
Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi‐Pavlovic, D., Leyden, J., Harper, S., Somogyi, A. A., Lai, R., Weickert, C. S., et al. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12572 · Cited by 257 · cited 1×
“They also cited studies of intramuscular and subcutaneous administration, sublingual administration, and transmucosal routes (Lara et al., 2013; Nguyen et al., 2015; Loo et al., 2016).”
BackgroundAltshuler, L. L., Bauer, M., Frye, M. A., Gitlin, M. J., Mintz, J., Szuba, M. P., Leight, K. L., & Whybrow, P. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1617 · Cited by 250 · cited 2×
“They commented that existing studies predominantly assessed TCA augmentation (Altshuler et al., 2001), with STAR*D being the only evidence of efficacy with SSRIs at the time of publication (Nierenberg et al.”
BackgroundRisperidone Augmentation of Selective Serotonin Reuptake Inhibitors in Major Depression
Ostroff, R. B., & Nelson, J. C. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0410 · Cited by 248
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246 · cited 25×
“The guidance from BAP regarding modafinil augmentation is limited, as they stated that there is only preliminary evidence for its use over the short term and cited the same meta-analysis of 4 MDD RCTs as CANMAT (Goss et al., 2013).”
BackgroundMethodInfluentialPapakostas, G. I., Shelton, R. C., Smith, J., & Fava, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0602 · Cited by 241
The role of ketamine in treatment-resistant depression: A systematic review
Serafini, G., Howland, R., Rovedi, F., Girardi, P., & Amore, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140619204251 · Cited by 234
Lithium for maintenance treatment of mood disorders
Burgess, S. S., Geddes, J., Hawton, K. K., Taylor, M. J., Townsend, E., Jamison, K., & Goodwin, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003013 · Cited by 232 · cited 2×
“Evidence for lithium monotherapy in prophylaxis not sufficient (Souza and Goodwin, 1991; Burgess et al., 2001), but more recent meta-analysis showed efficacy of lithium when used for preventative purposes, though relative efficacy was not (Cipriani et al.”
BackgroundKetamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression
Wan, L.-B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., Foulkes, A., Mathew, S. J., Charney, D. S., & Murrough, J. W. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08852 · Cited by 231 · cited 1×
“CANMAT recommend ketamine as an experimental adjunctive agent in an academic setting but echoed caution against adverse reactions, potential abuse, and its efficacy long term (Fond et al., 2014b; Serafini et al., 2014a; Coyle and Laws, 2015; Wan et al., 2015).”
BackgroundThase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Clayton, A. H., Warnock, J. K., Kornstein, S. G., Pinkerton, R., Sheldon-Keller, A., & McGarvey, E. L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0110 · Cited by 222
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1372 · Cited by 216 · cited 2×
“The ICSI also noted studies in which increasing the antidepressant dose proved more effective than adding lithium (Fava et al., 1994; Perry et al., 1994).”
BackgroundBOBES, J., GARC A-PORTILLA, M. P., REJAS, J., HERN NDEZ, G., GARCIA-GARCIA, M., RICO-VILLADEMOROS, F., & PORRAS, A. (2003) · Journal of Sex & Marital Therapy · doi:10.1080/713847170 · Cited by 213
Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended
Leucht, S., Busch, R., Hamann, J., Kissling, W., & Kane, J. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.023 · Cited by 213 · cited 2×
“ECG BAP, TMAP, MPG Pregnancy test (as indicated) TMAP Extrapyramidal side effects TMAP Weight/BMI NICE, TMAP, MPG Glucose levels NICE, TMAP, MPG Lipid levels NICE, TMAP, MPG Sexual function enquiry TMAP Prolactin level TMAPa, MPG Ocular evaluations TMAP Urea and electrolytes MPG (Leucht et al., 2005; Agid et al., 2006…”
MethodThe science and practice of lithium therapy
Malhi, G. S., Tanious, M., Das, P., & Berk, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412437346 · Cited by 209
Lithium Treatment Reduces Suicide Risk in Recurrent Major Depressive Disorder
Guzzetta, F., Tondo, L., Centorrino, F., & Baldessarini, R. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0304 · Cited by 208 · cited 1×
“WFSBP noted that lithium was effective in preventing suicide/suicide attempts, but it is not known if it has acute antisuicide effects (Coppen et al., 1990; Thies-Flechtner et al., 1996; Tondo et al., 1997; Müller-Oerlinghausen, 1999; Schou, 2000; Guzzetta et al., 2007; Lauterbach et al., 2008; Cipriani et al., 2013).”
BackgroundFava, M., Thase, M. E., & DeBattista, C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0112 · Cited by 207
Effect of Prophylactic Treatment on Suicide Risk in Patients with Major Affective Disorders
Thies-Flechtner, K., Müller-Oerlinghausen, B., Seibert, W., Walther, A., & Greil, W. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979553 · Cited by 205
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs
Peluso, M. J., Lewis, S. W., Barnes, T. R. E., & Jones, P. B. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.101485 · Cited by 196
Monoamine Oxidase Inhibitors:A Modern Guide to an Unrequited Class of Antidepressants
Stahl, S. M., & Felker, A. (2008) · CNS Spectrums · doi:10.1017/s1092852900016965 · Cited by 191
DeBattista, C., Doghramji, K., Menza, M. A., Rosenthal, M. H., Fieve, R. R., & Modafinil in Depression Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0911 · Cited by 189
Zhou, X., Ravindran, A. V., Qin, B., Del Giovane, C., Li, Q., Bauer, M., Liu, Y., Fang, Y., da Silva, T., Zhang, Y., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09204 · Cited by 189 · cited 4×
“Thyroid hormone recommendations also varied despite all guidelines having the same RCT evidence base to draw on, as all RCT evidence in TRD was published prior to 2008 (Zhou et al., 2015; Strawbridge et al., 2019).”
BackgroundMethodInfluentialInteractions Between Antiepileptic Drugs and Hormonal Contraception
Crawford, P. (2002) · CNS Drugs · doi:10.2165/00023210-200216040-00005 · Cited by 189 · cited 2×
“They advised that carbamazepine may reduce the levels of most antipsychotics (Crawford, 2002; Patsalos et al., 2002; Spina and Perucca, 2002; Citrome et al., 2007).”
BackgroundEl-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 185
Lithium and the Kidney: An Updated Review
Gitlin, M. J. (1999) · Drug Safety · doi:10.2165/00002018-199920030-00004 · Cited by 184
Lithium: a review of its metabolic adverse effects
Livingstone, C., & Rampes, H. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881105057515 · Cited by 184
Renal failure occurs in chronic lithium treatment but is uncommon
Bendz, H., Schön, S., Attman, P.-O., & Aurell, M. (2010) · Kidney International · doi:10.1038/ki.2009.433 · Cited by 183
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Bauer, M., Bschor, T., Kunz, D., Berghöfer, A., Ströhle, A., & Müller-Oerlinghausen, B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1429 · Cited by 176
Adli, M., Baethge, C., Heinz, A., Langlitz, N., & Bauer, M. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0579-5 · Cited by 174 · cited 1×
“, 2003), a systematic review of 11 studies in which antidepressant dose increase was no less effective than augmentation with either lithium or desipramine (Adli et al., 2005), and the 2007 comparison of lithium and quetiapine augmentation demonstrating no significant difference, also mentioned in relation to quetiapi…”
BackgroundBaumann, P., Nil, R., Souche, A., Montaldi, S., Baettig, D., Lambert, S., Uehlinger, C., Kasas, A., Amey, M., & Jonzier-Perey, M. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199608000-00006 · Cited by 173
Second-generation antipsychotics for major depressive disorder and dysthymia
Komossa, K., Depping, A. M., Gaudchau, A., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008121.pub2 · Cited by 171 · cited 3×
“CANMAT referred to 4 additional meta-analyses (again including Nelson and Papakostas, 2009), each including 12–17 trials and reporting better efficacy for aripiprazole, quetiapine, olanzapine, and risperidone compared with placebo, with small to medium effect sizes (Komossa et al., 2010; Spielmans et al., 2013; Wen et…”
BackgroundMethodResultCorya, S. A., Williamson, D., Sanger, T. M., Briggs, S. D., Case, M., & Tollefson, G. (2006) · Depression and Anxiety · doi:10.1002/da.20130 · Cited by 170 · cited 1×
“trials report rapid improvements in mood, but the difference is modest compared with placebo (Shelton et al., 2001; Corya et al., 2006; Berman et al., 2007; Dorée et al., 2007; Mahmoud et al., 2007; McIntyre et al., 2007; Thase et al., 2007a; Garakani et al., 2008; Keitner et al., 2009).”
ResultTreatment of Refractory Depression with High-Dose Thyroxine
Bauer, M., Hellweg, R., Gräf, K. J., & Baumgartner, A. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00181-4 · Cited by 170
Rapaport, M. H., Gharabawi, G. M., Canuso, C. M., Mahmoud, R. A., Keller, M. B., Bossie, C. A., Turkoz, I., Lasser, R. A., Loescher, A., Bouhours, P., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301113 · Cited by 168
A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants
Joffe, R. T., & Singer, W. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90029-5 · Cited by 167 · cited 1×
“NICE also noted 1 study in which T4 was inferior to T3 (Joffe and Singer, 1990) but made no recommendations for T4.”
BackgroundForty Years of Lithium Treatment
Schou, M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130013002 · Cited by 165 · cited 1×
“Efficacy of lithium maintenance treatment well established (Coppen et al., 1990; Schou, 1997; Davis et al., 1999; Bauer et al., 2000; Paykel, 2001; Bschor et al., 2002).”
BackgroundBarbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Corya, S. A. (2005) · doi:10.4088/jcp.v66n1012 · Cited by 162 · cited 3×
“First-line recommendations The CPG-S included olanzapine as a first-line option, referring to 2 RCTs examining OFC, also included by NICE, in which the olanzapine group had nonsignificantly better response and remission rates vs placebo (Shelton et al., 2005; Thase et al., 2007a).”
BackgroundResultInfluentialClinically Significant Drug Interactions with Newer Antidepressants
Spina, E., Trifirò, G., & Caraci, F. (2012) · CNS Drugs · doi:10.2165/11594710-000000000-00000 · Cited by 160 · cited 1×
“CANMAT similarly cautioned against concomitant administration of cytochrome P450 inhibitors (Spina et al., 2012; Brandl et al., 2014).”
BackgroundBodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159 · cited 1×
“They also referred to several case series/case reports of bupropion augmentation that described beneficial results (Marshall and Liebowitz, 1996; Bodkin et al., 1997; Spier, 1998).”
BackgroundPlacebo-Controlled Trial of Lithium Augmentation of Fluoxetine and Lofepramine
Katona, C. L. E., Abou-Saleh, M. T., Harrison, D. A., Nairac, B. A., Edwards, D. R. L., Lock, T., Burns, R. A., & Robertson, M. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.1.80 · Cited by 158 · cited 1×
“Seven placebo-controlled trials demonstrating the efficacy of lithium augmentation were mentioned, though not all were referenced (Delgado et al., 1988; Joffe et al., 1993; Katona et al., 1995; Baumann et al., 1996).”
BackgroundPsychostimulants for depression
Candy, B., Jones, L., Williams, R., Tookman, A., & King, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006722.pub2 · Cited by 156
Thioridazine and sudden unexplained death in psychiatric in-patients
Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., & Thomas, S. H. L. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.6.515 · Cited by 156
Appelberg, B. G., Syvalahti, E. K., Koskinen, T. E., Mehtonen, O.-P., Muhonen, T. T., & Naukkarinen, H. H. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0608 · Cited by 155 · cited 20×
“The guidance from BAP regarding modafinil augmentation is limited, as they stated that there is only preliminary evidence for its use over the short term and cited the same meta-analysis of 4 MDD RCTs as CANMAT (Goss et al., 2013).”
BackgroundInfluentialLauterbach, E., Felber, W., Müller‐Oerlinghausen, B., Ahrens, B., Bronisch, T., Meyer, T., Kilb, B., Lewitzka, U., Hawellek, B., Quante, A., et al. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01266.x · Cited by 154 · cited 1×
“WFSBP noted that lithium was effective in preventing suicide/suicide attempts, but it is not known if it has acute antisuicide effects (Coppen et al., 1990; Thies-Flechtner et al., 1996; Tondo et al., 1997; Müller-Oerlinghausen, 1999; Schou, 2000; Guzzetta et al., 2007; Lauterbach et al., 2008; Cipriani et al., 2013).”
BackgroundSexual side-effects of antidepressant and antipsychotic drugs
Baldwin, D., & Mayers, A. (2003) · Advances in Psychiatric Treatment · doi:10.1192/apt.9.3.202 · Cited by 154
Lithium-associated clinical hypothyroidism: Prevalence and risk factors
Johnston, A. M., & Eagles, J. M. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.4.336 · Cited by 153
Landen, M., Bjorling, G., Agren, H., & Fahlen, T. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1204 · Cited by 149
Diav-Citrin, O., Shechtman, S., Tahover, E., Finkel-Pekarsky, V., Arnon, J., Kennedy, D., Erebara, A., Einarson, A., & Ornoy, A. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.12111402 · Cited by 149
A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning
Knegtering, R., Castelein, S., Bous, H., van der Linde, J., Bruggeman, R., Kluiter, H., & van den Bosch, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106220.36344.04 · Cited by 147
Hoffmann-Eßer, W., Siering, U., Neugebauer, E. A. M., Brockhaus, A. C., McGauran, N., & Eikermann, M. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-2954-8 · Cited by 146 · cited 1×
“Scaled scores were calculated for each of the 6 domains according to the instruction manual (Hoffmann-Eßer et al., 2018).”
MethodMcIntyre, A., Gendron, A., & McIntyre, A. (2007) · Depression and Anxiety · doi:10.1002/da.20275 · Cited by 145
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144 · cited 1×
“The MGP featured modafinil in their “other reported treatments” section due to the lack of evidence supporting its use as an adjunctive treatment (Fawcett et al., 1991; DeBattista et al., 2004; Lavretsky et al., 2006; Taneja et al., 2007) and stated that other augmentation options are better supported, as the evidence…”
BackgroundLithium Treatment and Prophylaxis in Unipolar Depression: A Meta-analysis
Souza, F. G. M., & Goodwin, G. M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.5.666 · Cited by 144 · cited 1×
“Evidence for lithium monotherapy in prophylaxis not sufficient (Souza and Goodwin, 1991; Burgess et al., 2001), but more recent meta-analysis showed efficacy of lithium when used for preventative purposes, though relative efficacy was not (Cipriani et al.”
BackgroundClinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs
Spina, E., & Perucca, E. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2037.x · Cited by 143 · cited 1×
“They advised that carbamazepine may reduce the levels of most antipsychotics (Crawford, 2002; Patsalos et al., 2002; Spina and Perucca, 2002; Citrome et al., 2007).”
BackgroundEffect of Lithium Maintenance on. Suicidal Behavior in Major Mood Disordersa
TONDO, L., JAMISON, K. R., & BALDESSARINI, R. J. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb52369.x · Cited by 142
Fava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Nelson, J. C., Baumann, P., Delucchi, K., Joffe, R. T., & Katona, C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.053 · Cited by 141
Results of phase 3 of the CATIE schizophrenia trial
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Davis, S. M., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. K. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.011 · Cited by 141 · cited 1×
“, 2013), MPG Coronary heart disease/risk of sudden cardiac death MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013) Extrapyramidal side effects (including tardive dyskinesia and neuroleptic…”
BackgroundThyroid Hormone, Neural Tissue and Mood Modulation
Bauer, M., & Whybrow, P. C. (2001) · The World Journal of Biological Psychiatry · doi:10.3109/15622970109027495 · Cited by 140 · cited 1×
“WFSBP stated that the evidence base for T3 consisted of many case series and 13 prospective trials at the time of publication (9 open-label and 4 double-blind RCTs) and most augmented TCAs in TCA nonresponders (Joffe et al., 1993; Altshuler et al., 2001; Bauer and Whybrow, 2001).”
BackgroundPatkar, A. A., Masand, P. S., Pae, C.-U., Peindl, K., Hooper-Wood, C., Mannelli, P., & Ciccone, P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246212.03530.fd · Cited by 140
Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140 · cited 2×
“First-line recommendations The BAP recommended risperidone as first line, as did CANMAT (Level I evidence), and the CPG-S, who referred to 3 studies included in the current NICE guidelines in which there was no significant difference in depression severity or discontinuation due to adverse effects between risperidone…”
ResultAugmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., de Angel, V., Patrick, F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.233 · Cited by 140 · cited 26×
“Some differences may relate to variation in the point at which guidelines recommended augmentation, as (Strawbridge et al., 2019) reported just 1 RCT examining T3 in patients with 2 or more failed antidepressant treatment trials in their current episode of depression, while (Zhou et al.”
BackgroundResultInfluentialSelf-citationPERRY, P. J., ZEILMANN, C., & ARNDT, S. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199408000-00002 · Cited by 138
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 138 · cited 1×
“They also cited studies of intramuscular and subcutaneous administration, sublingual administration, and transmucosal routes (Lara et al., 2013; Nguyen et al., 2015; Loo et al., 2016).”
BackgroundHaro, J. M., Novick, D., Suarez, D., Alonso, J., Lépine, J. P., & Ratcliffe, M. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000246215.49271.b8 · Cited by 137
Liperoti, R., Gambassi, G., Lapane, K. L., Chiang, C., Pedone, C., Mor, V., & Bernabei, R. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.6.696 · Cited by 136 · cited 1×
“, 2013), MPG Coronary heart disease/risk of sudden cardiac death MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013) Extrapyramidal side effects (including tardive dyskinesia and neuroleptic…”
BackgroundZhu, Y., Krause, M., Huhn, M., Rothe, P., Schneider‐Thoma, J., Chaimani, A., Li, C., Davis, J. M., & Leucht, S. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30270-5 · Cited by 136 · cited 2×
“Glucose levels NICE, TMAP, MPG Lipid levels NICE, TMAP, MPG Sexual function enquiry TMAP Prolactin level TMAPa, MPG Ocular evaluations TMAP Urea and electrolytes MPG (Leucht et al., 2005; Agid et al., 2006; Zhang et al., 2013; Subotnik et al., 2015; Zhu et al., 2017; Robinson et al., 2018) Full blood count MPG (Leucht…”
BackgroundMethodGoss, A. J., Kaser, M., Costafreda, S. G., Sahakian, B. J., & Fu, C. H. Y. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08560 · Cited by 133 · cited 37×
“NICE did not recommend lamotrigine, carbamazepine, or valproate as they considered the evidence inadequate at the time of publication (Hurley, 2002; Normann et al., 2002; Barbosa et al., 2003; Schindler and Anghelescu, 2007b; Santos et al., 2008) as did CANMAT (Zhou et al., 2015).”
BackgroundMethodInfluentialImprovement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Walker, P. W., Cole, J. O., Gardner, E. A., Hughes, A. R., Johnston, J. A., Batey, S. R., & Lineberry, C. G. (1993) · PubMed · Cited by 132
Ashley, C., & Dunleavy, A. (2017) · CRC Press eBooks · doi:10.1201/9780429460418 · Cited by 130
Remington, G., Kwon, J. S., COLLINS, A., Laporte, D., MANN, S., & Christensen, B. K. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.11.015 · Cited by 129
Tohen, M., McDonnell, D. P., Case, M., Kanba, S., Ha, K., Fang, Y. R., Katagiri, H., & Gomez, J.-C. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.108357 · Cited by 128
Depression, IV: STAR*D Treatment Trial for Depression
Rush, A. J., Trivedi, M. H., & D, M. F. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.237 · Cited by 126 · cited 1×
“Again, STAR*D was highlighted, as dropout was greater in patients taking buspirone compared with bupropion augmentation (Rush et al., 2003).”
BackgroundPapakostas, G. I., Petersen, T. J., Kinrys, G., Burns, A. M., Worthington, J. J., Alpert, J. E., Fava, M., & Nierenberg, A. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1017 · Cited by 125
Role of Lithium Augmentation in the Management of Major Depressive Disorder
Bauer, M., Adli, M., Ricken, R., Severus, E., & Pilhatsch, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0152-8 · Cited by 122
The Pharmacokinetics of Paliperidone Versus Risperidone
de León, J., Wynn, G. H., & Sandson, N. B. (2010) · Psychosomatics · doi:10.1016/s0033-3182(10)70664-2 · Cited by 121
Dossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121
Mood stabilizers in the prevention of recurrent affective disorders: a meta‐analysis
Davis, J. M., Janicak, P. G., & Hogan, D. M. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb10890.x · Cited by 120 · cited 1×
“Efficacy of lithium maintenance treatment well established (Coppen et al., 1990; Schou, 1997; Davis et al., 1999; Bauer et al., 2000; Paykel, 2001; Bschor et al., 2002).”
BackgroundRavindran, A. V., Kennedy, S. H., O'Donovan, M. C., Fallu, A., Camacho, F., & Binder, C. E. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0112 · Cited by 119
CNS Stimulant Potentiation of Monoamine Oxidase: Inhibitors in Treatment-Refractory Depression
FAWCETT, J., KRAVITZ, H. M., ZAJECKA, J. M., SCHAFF, M. R., & FREISHTAT, H. W. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199104000-00010 · Cited by 118 · cited 1×
“…stated that other augmentation options are better supported, as the evidence for stimulants (methylphenidate, dexamfetamine, and lisdexamfetamine) is generally inconclusive and inadequate (Fawcett et al., 1991; Parker and Brotchie, 2010; Trivedi et al., 2013; Madhoo et al., 2014; Israel, 2015).”
BackgroundRenal Insufficiency in Long-Term Lithium Treatment
Lepkifker, E., Sverdlik, A., Iancu, I., Ziv, R., Segev, S., & Kotler, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0618 · Cited by 118
Stein, G., & Bernadt, M. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.5.634 · Cited by 118 · cited 1×
“They included 10 eligible RCTs, all of which were between 1 and 6 weeks in length and had been included in their previous guidelines (Zusky et al., 1988; Jensen et al., 1992; Joffe et al., 1993; Stein and Bernadt, 1993; Baumann et al., 1996; Shahal et al., 1996; Bloch et al., 1997; Cappiello et al., 1998; Januel et al…”
BackgroundBupropion for Smoking Cessation in Patients Hospitalized With Acute Myocardial Infarction
Eisenberg, M. J., Grandi, S. M., Gervais, A., O’Loughlin, J. L., Paradis, G., Rinfret, S., Sarrafzadegan, N., Sharma, S., Lauzon, C., Yadav, R. K., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1030 · Cited by 113
Agid, O., Seeman, P., & Kapur, S. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0611 · Cited by 110 · cited 2×
“ECG BAP, TMAP, MPG Pregnancy test (as indicated) TMAP Extrapyramidal side effects TMAP Weight/BMI NICE, TMAP, MPG Glucose levels NICE, TMAP, MPG Lipid levels NICE, TMAP, MPG Sexual function enquiry TMAP Prolactin level TMAPa, MPG Ocular evaluations TMAP Urea and electrolytes MPG (Leucht et al., 2005; Agid et al., 2006…”
MethodPsychiatric adverse events during vigabatrin therapy
Levinson, D. F., & Devinsky, O. (1999) · Neurology · doi:10.1212/wnl.53.7.1503 · Cited by 110 · cited 1×
“APA also cautioned that anticonvulsant compounds may negatively impact mood (Schmitz, 2002), as some, including barbiturates and potentially vigabatrin, have been associated with an increased risk of depression (Levinson and Devinsky, 1999) supported by a statement from the US Food and Drug Administration (Kuehn, 2008…”
BackgroundFava, M., Thase, M. E., DeBattista, C., Doghramji, K., Arora, S., & Hughes, R. J. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701464858 · Cited by 109
Keitner, G. I., Garlow, S. J., Ryan, C. E., Ninan, P. T., Solomon, D. A., Nemeroff, C. B., & Keller, M. B. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.05.003 · Cited by 108 · cited 5×
“Several side effects were highlighted as disadvantages (Ostroff and Nelson, 1999; Stoll and Haura, 2000; Rapaport et al., 2006; Mahmoud et al., 2007; Yoshimura et al., 2008; Keitner et al., 2009).”
BackgroundResultInfluentialLamotrigine as Adjunct to Paroxetine in Acute Depression: A Placebo-Controlled, Double-Blind Study
Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H., & Walden, J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0411 · Cited by 107
Standardisation framework for the Maudsley staging method for treatment resistance in depression
Fekadu, A., Donocik, J. G., & Cleare, A. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1679-x · Cited by 106
Self-citationCombined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression.
Feighner, J. P., Herbstein, J., & Damlouji, N. F. (1985) · PubMed · Cited by 105
Brosseau, L., Rahman, P., Toupin-April, K., Poitras, S., King, J., De Angelis, G., Loew, L., Casimiro, L., Paterson, G., & McEwan, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082986 · Cited by 105 · cited 1×
“Guidelines with 3 or more domains scoring μ ≥ 60% were included, as this cut-off has been used by previous appraisals to indicate that a guideline is of reasonable quality (Brosseau et al., 2014).”
MethodSimon, J. S., & Nemeroff, C. B. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1002 · Cited by 103 · cited 1×
“The MPG included aripiprazole as first line, advocating a good evidence base, good tolerability and safety, and the potential efficacy of low doses, though side effects may be disadvantageous (Papakostas et al., 2005; Simon and Nemeroff, 2005; Berman et al., 2007; Hellerstein et al., 2008; Marcus et al., 2008; Fava et…”
BackgroundLithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants
Nierenberg, A. A., Papakostas, G. I., Petersen, T., Montoya, H. D., Worthington, J. J., Tedlow, J., Alpert, J. E., & Fava, M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00013 · Cited by 103
Reeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population
Pérez‐Iglesias, R., Mata, I. F., Pelayo‐Terán, J. M., Amado, J., García‐Unzueta, M. T., Berja, A., Martínez‐García, O., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.028 · Cited by 102
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, C. E., Severe, J., et al. (2006) · Focus · doi:10.1176/foc.4.4.539 · Cited by 102
Bauer, M., El-Khalili, N., Datto, C. J., Szamosi, J., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.032 · Cited by 100
Antipsychotic-Induced Hyponatraemia
Meulendijks, D., Mannesse, C. K., Jansen, P. A. F., van Marum, R. J., & Egberts, T. C. G. (2010) · Drug Safety · doi:10.2165/11319070-000000000-00000 · Cited by 100 · cited 2×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundLamotrigine as an Augmentation Agent in Treatment-Resistant Depression
Barbee, J. G., & Jamhour, N. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0813 · Cited by 97
Lithium Augmentation in Antidepressant-Resistant Patients a Quantitative Analysis
Austin, M.-P. V., Souza, F. G. M., & Goodwin, G. M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.4.510 · Cited by 97 · cited 1×
“Second-line recommendations APA included lithium with Level II (moderate) confidence and stated that it is the most widely studied adjunctive treatment for this patient group, has the potential to reduce the risk of suicide, and has efficacy in preventing relapse (Austin et al., 1991; Bauer and Dopfmer, 1999; Cipriani…”
BackgroundLithium in the treatment of major depressive disorder
Bschor, T. (2014) · Drugs · doi:10.1007/s40265-014-0220-x · Cited by 94
Lithium versus antidepressants in the long-term treatment of unipolar affective disorder
Cipriani, A., Smith, K. A., Burgess, S. S., Carney, S. M., Goodwin, G., & Geddes, J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003492.pub2 · Cited by 91 · cited 4×
“Second-line recommendations APA included lithium with Level II (moderate) confidence and stated that it is the most widely studied adjunctive treatment for this patient group, has the potential to reduce the risk of suicide, and has efficacy in preventing relapse (Austin et al., 1991; Bauer and Dopfmer, 1999; Cipriani…”
BackgroundInfluentialSexual Side Effects of Pharmacological Treatment of Psychiatric Diseases
Serretti, A., & Chiesa, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.70 · Cited by 91
Lavretsky, H., Park, S., Siddarth, P., Kumar, A., & Reynolds, C. F. (2006) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192503.10692.9f · Cited by 90 · cited 2×
“APA also advised that methylphenidate or dextroamphetamine may be useful (Masand et al., 1998; Lavretsky et al., 2006; Ravindran et al., 2008) but cautioned that not all clinical trials have shown benefits (Patkar et al.”
BackgroundLam, R. W., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88 · cited 2×
“, 2006a) but highlighted that it is not licensed for use in depression in the United Kingdom (Fatemi et al., 1999; Pierre and Gitlin, 2000; Lam et al., 2004; Papakostas et al., 2006b; Zisook et al., 2010; Henssler et al., 2016).”
BackgroundKelly, D. L., & Conley, R. R. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.010 · Cited by 88
Liebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010) · Depression and Anxiety · doi:10.1002/da.20740 · Cited by 86 · cited 7×
“The guidance from BAP regarding modafinil augmentation is limited, as they stated that there is only preliminary evidence for its use over the short term and cited the same meta-analysis of 4 MDD RCTs as CANMAT (Goss et al., 2013).”
BackgroundInfluentialEffects of 10 to 30 years of lithium treatment on kidney function
Aiff, H., Attman, P.-O., Aurell, M., Bendz, H., Ramsauer, B., Schön, S., & Svedlund, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115573808 · Cited by 86
Wright, B. M., Eiland, E. H., & Lorenz, R. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1204 · Cited by 84
Quetiapine augmentation of treatment-resistant depression: a comparison with lithium
Dorée, J.-P., Rosiers, J. D., Lew, V., Gendron, A., Elie, R., Stip, E., & Valérie Tourjman, S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162809 · Cited by 84 · cited 4×
“Other evidence considered by the CPG-S included the RCT comparison of lithium and CBT discussed by BAP (Kennedy et al., 2003), a systematic review of 11 studies in which antidepressant dose increase was no less effective than augmentation with either lithium or desipramine (Adli et al., 2005), and the 2007 comparison…”
BackgroundResultInfluentialLithium prophylaxis: myths and realities
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.573 · Cited by 83
Atasoy, N., Erdoğan, A., Yaluğ, İ., Öztürk, Ü. A., Konuk, N., Atik, L., & Üstündağ, Y. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.005 · Cited by 82
Barbee, J. G., Thompson, T. R., Jamhour, N. J., Stewart, J. W., Conrad, E. J., Reimherr, F. W., Thompson, P. M., & Shelton, R. C. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05355gre · Cited by 78
Barbui, C., Conti, V., & Cipriani, A. (2014) · Drug Safety · doi:10.1007/s40264-013-0127-6 · Cited by 78
Cooper-Kazaz, R., & Lerer, B. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008206 · Cited by 78 · cited 2×
“RANZCP emphasized the mixed evidence for T3, highlighting a 2008 review (Cooper-Kazaz and Lerer, 2008), but advised that T3 augmentation should be used in those with and without subclinical hypothyroidism.”
BackgroundBayes, A. J., & Parker, G. B. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12878 · Cited by 77 · cited 1×
“A recent review of treatment guidelines for depression included pharmacotherapy and neuro-stimulation but very little information pertaining to pharmacological augmentation (Bayes and Parker, 2018).”
Research works printed but not linked: 12
- Agid, 2006, The “delayed onset” of antipsychotic action–an idea whose time has come and gone, J Psychiatry Neurosci, 31, 93
- DeBattista, 2003, Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study, J Clin Psychiatry, 64, 1057, 10.4088/JCP.v64n0911 · DOI · Paper page
- FDA, 2019, February 12, 2019: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee - 02/12/2019 - 02/12/2019
- Fond, 2014, Ketamine administration in depressive disorders: a systematic review and meta-analysis, Psychopharmacology (Berl), 231, 3663, 10.1007/s00213-014-3664-5 · DOI · Paper page
- Hurley, 2002, Lamotrigine update and its use in mood disorders, Ann Pharmacother, 36, 860, 10.1345/aph.1A102 · doi:10.1345/aph.1a102 · Paper page
- Jensen, 1992, Combining nortriptyline and lithium in elderly depressed patients: a double-blind, placebo-controlled study, Lithium, 3, 259
- National Institute for Health and Clinical Excellence (NICE), 2009, The treatment and management of depression in adults (Updated Edition)
- Schindler, 2007, Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study, Int Clin Psychopharmacol, 22, 179, 10.1097/YIC.0b013e328014823d · DOI · Paper page
- Serafini, 2014, The role of ketamine in treatment-resistant depression: a systematic review, Curr Neuropharmacol, 12, 444, 10.2174/1570159X12666140619204251 · DOI · Paper page
- Suehs, 2008, Texas medication algorithm project procedural manual: major depressive disorder algorithms. Austin, TX: The Texas Department of State Health Services
- Taylor, 2015, The Maudsley prescribing guidelines in psychiatry
- Trivedi, 2006, Medication augmentation after the failure of SSRIs for depression, N Engl J Med, 354, 1243, 10.1056/NEJMoa052964 · DOI · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“Moreover, guidelines on how to treat TRD/PRD, such as pharmacological augmentation, are not consistent [14], and evidence on effectiveness is sparse [15].”
BackgroundSelf-citationMalhi, G. S., Bell, E., Singh, A., Bassett, D. L., Berk, M., Boyce, P. M., Bryant, R. A., Gitlin, M. J., Hamilton, A., Hazell, P., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.13035 · Cited by 131
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“The exception to this rule was buspirone, for which the ES and 95% CIs were considerably higher when TRD was defined as 2 FTs (1 FT = ES = 0.84, 95% CI: 0.61–1.07; 2 FTs = ES = 1.57, 95% CI: 1.14–2.02), although this consisted of only one small study.”
BackgroundResultInfluentialSelf-citationLevkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health · doi:10.1136/fmch-2023-002391 · Cited by 83
“Scrutiny and handling of gender or socioeconomic biases.”
Background
Metadata
- Authors
- Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J.
- Affiliations
- King's College London (GB)
- The Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, London, United Kingdom
- Oxford Health NHS Foundation Trust (GB)
- University of Geneva (CH)
- Corresponding author
- Marwood, Lindsey
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-13
- Volume
- 23
- Issue
- 9
- Pages
- 587-625
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7710919
- OpenAlex
- W3024119889
- Cited by
- 76
- References
- 341
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 16 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute for Health Research
- South London and Maudsley NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- drug augmentation, treatment-resistant depression, major depressive disorder, guideline quality, lithium, atypical antipsychotics, polypharmacy, evidence-based care, guideline recommendations
- MeSH terms
- Major Depressive Disorder, Drug Synergism, Drug Therapy, Combination, Humans, Drug Prescriptions, Antipsychotic Agents, Practice Guidelines as Topic, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
